MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway Retraction in /10.3892/ijmm.2022.5181

Zhao,Xiwu; Li,Jian; Yu,Dapeng

doi:10.3892/ijmm.2019.4333

MicroRNA-939-5p directly targets IGF-1R to inhibit the aggressive phenotypes of osteosarcoma through deactivating the PI3K/Akt pathway

Retraction in: /10.3892/ijmm.2022.5181

Authors:
- Xiwu Zhao
- Jian Li
- Dapeng Yu
View Affiliations

Affiliations: Department of Traumatic Orthopedics, Shandong Provincial Western Hospital, Jinan, Shandong 250022, P.R. China, Department of Orthopedics, Jinan Fourth People's Hospital, Jinan, Shandong 250031, P.R. China, Department of Spine Surgery, Shandong Provincial Western Hospital, Jinan, Shandong 250022, P.R. China
Published online on: September 5, 2019 https://doi.org/10.3892/ijmm.2019.4333
Pages: 1833-1843
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The dysregulation of microRNA‑939‑5p (miR‑939) is involved in the development of multiple types of human cancer. However, the expression and roles of miR‑939 in osteosarcoma (OS) have yet to be clarified. The expression level of miR‑939 in OS was measured using reverse transcription quantitative polymerase chain reaction (RT‑qPCR). A Cell Counting Kit‑8 assay, flow cytometry analysis, Transwell migration and invasion assays, and a tumor xenograft assay were employed to explore the effects of miR‑939 in OS cells. Bioinformatics analysis, RT‑qPCR, western blot analysis and luciferase reporter assays were performed to explore its underlying mechanism. Expression of miR‑939 was decreased in both OS tissues and cell lines. The decreased miR‑939 expression was notably correlated with clinical stage and distant metastasis in patients with OS, where low miR‑939 levels were correlated with lower overall survival. miR‑939 overexpression decreased OS cell proliferation, migration and invasion in vitro; induced cell apoptosis, and impaired tumor growth in vivo. Mechanistically, insulin‑like growth factor 1 receptor (IGF‑1R) was characterized as direct target gene of miR‑939 in OS. The tumor‑suppressing effects of miR‑939 in OS cells were imitated by IGF‑1R knockdown. In addition, exogenous IGF‑1R expression abolished the tumor suppressive roles of miR‑939 in OS cells. miR‑939 was implicated in the deactivation of the PI3K/Akt pathway in OS in vitro and in vivo through regulating IGF‑1R expression. The present study demonstrated that miR‑939 exerted tumor‑suppressing roles in the malignancy of OS cells by directly targeting IGF‑1R and inactivating the PI3K/AKT pathway. Therefore, this miRNA may be a promising target for anticancer therapy in patients with OS.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
2	Kager L, Zoubek A, Dominkus M, Lang S, Bodmer N, Jundt G, Klingebiel T, Jürgens H and Gadner H: Osteosarcoma in very young children: Experience of the cooperative osteosarcoma study group. Cancer. 116:5316–5324. 2010. View Article : Google Scholar : PubMed/NCBI
3	Geller DS and Gorlick R: Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.
4	Sun L, Li Y, Zhang J, Li H, Li B and Ye Z: Prognostic value of pathologic fracture in patients with high grade localized osteo-sarcoma: A systemic review and meta-analysis of cohort studies. J Orthop Res. 33:131–139. 2015. View Article : Google Scholar
5	Li S, Zhang T, Xu W, Ding J, Yin F, Xu J, Sun W, Wang H, Sun M, Cai Z and Hua Y: Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics. 8:1361–1375. 2018. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Wang F, Li M, Yu Z, Qi R, Ding J, Zhang Z and Chen X: Self-stabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma. Adv Sci (Weinh). 5:pp. 17008212018, View Article : Google Scholar
7	Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
8	Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, Unterberg A, Karapanagiotou-Schenkel I, Combs SE, Nikoghosyan A, et al: Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer. 10:962010. View Article : Google Scholar : PubMed/NCBI
9	Errani C, Longhi A, Rossi G, Rimondi E, Biazzo A, Toscano A, Alì N, Ruggieri P, Alberghini M, Picci P, et al: Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 11:217–227. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
11	Pasquinelli AE, Hunter S and Bracht J: MicroRNAs: A developing story. Curr Opin Genet Dev. 15:200–205. 2005. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jia F, Zhang Z and Zhang X: MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway. J Cell Biochem. 120:6420–6430. 2019. View Article : Google Scholar
14	Ma L, Shao Z and Zhao Y: MicroRNA-374a promotes pancreatic cancer cell proliferation and epithelial to mesenchymal transition by targeting SRCIN1. Pathol Res Pract. 215:1523822019. View Article : Google Scholar : PubMed/NCBI
15	Zhang Z and Dai DQ: MicroRNA-596 acts as a tumor suppressor in gastric cancer and is upregulated by promotor demethylation. World J Gastroenterol. 25:1224–1237. 2019. View Article : Google Scholar : PubMed/NCBI
16	Tang Z, Fang Y and Du R: MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer. Biochem Biophys Res Commun. 512:331–337. 2019. View Article : Google Scholar : PubMed/NCBI
17	Kim YH, Goh TS, Lee CS, Oh SO, Kim JI, Jeung SH and Pak K: Prognostic value of microRNAs in osteosarcoma: A meta-analysis. Oncotarget. 8:8726–8737. 2017.PubMed/NCBI
18	Kushlinskii NE, Fridman MV and Braga EA: Molecular mechanisms and microRNAs in osteosarcoma pathogenesis. Biochemistry (Mosc). 81:315–328. 2016. View Article : Google Scholar
19	Ying X, Li-ya Q, Feng Z, Yin W and Ji-hong L: MiR-939 promotes the proliferation of human ovarian cancer cells by repressing APC2 expression. Biomed Pharmacother. 71:64–69. 2015. View Article : Google Scholar : PubMed/NCBI
20	Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, et al: Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, identify cirrhotic patients with HCC. PLoS One. 10:pp. e01414482015, View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Liu X, Li Q and Zhang Y: lncRNA LINC00460 promoted colorectal cancer cells metastasis via miR-939-5p sponging. Cancer Manag Res. 11:1779–1789. 2019. View Article : Google Scholar : PubMed/NCBI
22	Chen Y, Guo Y and Yan W: lncRNA RP5-916L7.2 correlates with advanced tumor stage, and promotes cells proliferation while inhibits cells apoptosis through targeting miR-328 and miR-939 in tongue squamous cell carcinoma. Clin Biochem. 67:24–32. 2019. View Article : Google Scholar : PubMed/NCBI
23	Zhang JX, Xu Y, Gao Y, Chen C, Zheng ZS, Yun M, Weng HW, Xie D and Ye S: Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 16:182017. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015. View Article : Google Scholar
26	Liu W and Wang X: Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 20:182019. View Article : Google Scholar : PubMed/NCBI
27	Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, Zhu ZZ, Qian BP, Chen YX, Wang SF, et al: Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma. J Surg Oncol. 105:235–243. 2012. View Article : Google Scholar
28	Li YS, Liu Q, He HB and Luo W: The possible role of insulin-like growth factor-1 in osteosarcoma. Curr Prob Cancer. 43:228–235. 2019. View Article : Google Scholar
29	Wang YH, Wang ZX, Qiu Y, Xiong J, Chen YX, Miao DS and De W: Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem. 327:257–266. 2009. View Article : Google Scholar : PubMed/NCBI
30	Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF and Qiu Y: Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem. 341:225–233. 2010. View Article : Google Scholar : PubMed/NCBI
31	Chen L, Jiang X, Chen H, Han Q, Liu C and Sun M: MicroRNA-628 inhibits the proliferation of acute myeloid leukemia cells by directly targeting IGF-1R. OncoTargets Ther. 12:907–919. 2019. View Article : Google Scholar
32	Jiang W, Meng L, Xu G, Lv C, Wang H, Tian H, Chen R, Jiao B, Wang B and Huang C: Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R/IRS1/PI3K/AKT/ Nrf2/FLIP/Caspase-3 signaling pathway in small cell lung cancer. Oncol Lett. 16:6445–6457. 2018.PubMed/NCBI
33	Huang YK, Kang WM, Ma ZQ, Liu YQ, Zhou L and Yu JC: NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K/Akt/mTOR signaling pathway. Carcinogenesis. 40:370–379. 2019. View Article : Google Scholar
34	Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
35	Heng L, Jia Z, Bai J, Zhang K, Zhu Y, Ma J, Zhang J and Duan H: Molecular characterization of metastatic osteosar-coma: Differentially expressed genes, transcription factors and microRNAs. Mol Med Rep. 15:2829–2836. 2017. View Article : Google Scholar : PubMed/NCBI
36	Gurbuz N and Ozpolat B: MicroRNA-based targeted therapeutics in pancreatic cancer. Anticancer Res. 39:529–532. 2019. View Article : Google Scholar : PubMed/NCBI
37	Henry JC, Azevedo-Pouly AC and Schmittgen TD: MicroRNA replacement therapy for cancer. Pharm Res. 28:3030–3042. 2011. View Article : Google Scholar : PubMed/NCBI